Congress SMid Growth ETF
CSMD - ETF AI Analysis
Top Page
Congress SMid Growth ETF (CSMD)
CSMD’s rating suggests it is a generally solid growth-focused ETF, supported by strong contributors like Medpace Holdings and UFP Technologies, which show robust financial performance and promising growth opportunities in specialized medical markets. The fund is held back somewhat by weaker names like Rubrik, which faces profitability and valuation challenges, and by several holdings with high valuations or bearish technical signals, creating risk if growth expectations are not met. Overall, investors should be aware that many top holdings show strong momentum but also share risks related to overvaluation, leverage, or overbought technical conditions.
CSMD vs. SPDR S&P 500 ETF (SPY)
- AUM
- 489.24M
- Region
- North America
- Expense Ratio
- 0.68%
- Beta
- 0.99
- Issuer
- Congress
- Inception Date
- Aug 22, 2023
- Dividend Yield
- <0.01%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
CSMD Summary
Congress SMid Growth ETF (CSMD) is a U.S. stock fund focused on small and mid-sized companies with strong growth potential, rather than the usual large, well-known giants. It doesn’t track a specific index, but follows a growth theme across sectors like health care, technology, and industrials. Some recognizable names include BJ’s Wholesale Club and e.l.f. Beauty. Investors might consider CSMD to add diversification and higher growth potential to a portfolio by tapping into up-and-coming businesses. A key risk is that smaller growth companies can be more volatile, so the fund’s value can rise and fall sharply with market conditions.
How much will it cost me?
This ETF has an expense ratio of 0.68%, which means you’ll pay about $6.80 per year for every $1,000 you invest. That’s higher than the average ETF because it’s actively managed, with professionals selecting small- and mid-cap growth stocks rather than simply tracking an index.
What would affect this ETF?
This U.S.-focused ETF could benefit if small and mid-sized growth companies in health care and technology keep innovating and the economy remains supportive of business expansion, helping its top holdings like Halozyme, Rubrik, and other niche firms grow. On the downside, higher interest rates, an economic slowdown, or tighter regulations on health care and tech could hurt these smaller, growth-oriented companies more than large, established firms, making the ETF’s performance more volatile.
CSMD Top 10 Holdings
CSMD is leaning heavily into U.S. small and mid-cap health care and tech, with names like Halozyme, Ligand Pharma, and Medpace providing much of the fund’s current lift as their shares keep rising on solid growth stories. Rubrik and Samsara add a punchy software angle, also trending higher but with some valuation and profitability questions that could inject volatility. On the other side, Valmont and Repligen are more mixed, occasionally losing steam and tempering overall returns. Overall, it’s a focused, growth-first portfolio with a clear domestic, innovation-driven tilt.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Rubrik, Inc. Class A | 3.85% | $18.53M | $22.88B | 55.84% | 50Neutral | |
| Halozyme | 3.48% | $16.73M | $11.48B | 40.85% | 73Outperform | |
| Repligen | 3.35% | $16.11M | $10.64B | 11.44% | 68Neutral | |
| Ufp Technologies | 3.18% | $15.30M | $2.37B | 30.20% | 75Outperform | |
| Medpace Holdings | 3.15% | $15.14M | $18.37B | 10.59% | 79Outperform | |
| Bj's Wholesale Club Holdings | 3.12% | $15.00M | $14.01B | 17.40% | 71Outperform | |
| Valmont | 3.00% | $14.45M | $8.09B | 5.72% | 71Outperform | |
| e.l.f. Beauty | 2.86% | $13.74M | $6.72B | 58.60% | 68Neutral | |
| Ligand Pharma | 2.85% | $13.72M | $6.33B | 53.42% | 60Neutral | |
| Samsara | 2.85% | $13.71M | $24.20B | 6.82% | 69Neutral |
CSMD Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CSMD, the sentiment is Negative. The current price of 33.73 is below the 20-day moving average (MA) of 33.97, below the 50-day MA of 33.96, and below the 200-day MA of 33.80, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 48.01 is Neutral, neither overbought nor oversold. The STOCH value of 69.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CSMD.
CSMD Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $33.73 | $38.00(12.66% Upside) | $489.24M | 0.68% | 70Outperform | |
| $27.97 | $34.44(23.12% Upside) | $742.36M | 0.75% | 68Neutral | |
| $58.09 | $72.92(25.52% Upside) | $701.86M | 0.62% | 64Neutral | |
| $25.06 | $38.05(51.83% Upside) | $407.32M | 0.75% | 69Neutral | |
| $32.65 | $42.45(30.01% Upside) | $418.69M | 0.38% | 71Outperform | |
| $40.34 | $48.72(20.78% Upside) | $276.66M | 0.55% | 68Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CSMD | Congress SMid Growth ETF | 33.73 | 2.47 | 7.90% | |
| RSMC | Rockefeller U.S. Small-Mid Cap ETF | 27.97 | 3.34 | 13.56% | |
| MSSM | Morgan Stanley Pathway Small-Mid Cap Equity ETF | 58.09 | 10.27 | 21.47% | |
| GRNJ | Fundstrat Granny Shots US Small- & Mid-Cap ETF | 25.06 | 0.76 | 3.13% | |
| ASCE | Allspring SMID Core ETF | 32.65 | 7.59 | 30.30% | |
| SMIZ | Zacks Small/Mid Cap ETF | 40.34 | 4.66 | 13.06% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
